Insulin and Glucagon: Partners for Life

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Insulin and Glucagon : Partners for Life. / Holst, Jens Juul; Holland, William; Gromada, Jesper; Lee, Young; Unger, Roger H; Yan, Hai; Sloop, Kyle W; Kieffer, Timothy J; Damond, Nicolas; Herrera, Pedro L.

I: Endocrinology, Bind 158, Nr. 4, 01.04.2017, s. 696-701.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Holst, JJ, Holland, W, Gromada, J, Lee, Y, Unger, RH, Yan, H, Sloop, KW, Kieffer, TJ, Damond, N & Herrera, PL 2017, 'Insulin and Glucagon: Partners for Life', Endocrinology, bind 158, nr. 4, s. 696-701. https://doi.org/10.1210/en.2016-1748

APA

Holst, J. J., Holland, W., Gromada, J., Lee, Y., Unger, R. H., Yan, H., Sloop, K. W., Kieffer, T. J., Damond, N., & Herrera, P. L. (2017). Insulin and Glucagon: Partners for Life. Endocrinology, 158(4), 696-701. https://doi.org/10.1210/en.2016-1748

Vancouver

Holst JJ, Holland W, Gromada J, Lee Y, Unger RH, Yan H o.a. Insulin and Glucagon: Partners for Life. Endocrinology. 2017 apr. 1;158(4):696-701. https://doi.org/10.1210/en.2016-1748

Author

Holst, Jens Juul ; Holland, William ; Gromada, Jesper ; Lee, Young ; Unger, Roger H ; Yan, Hai ; Sloop, Kyle W ; Kieffer, Timothy J ; Damond, Nicolas ; Herrera, Pedro L. / Insulin and Glucagon : Partners for Life. I: Endocrinology. 2017 ; Bind 158, Nr. 4. s. 696-701.

Bibtex

@article{638431fd7fd04e46b3b57e4fc5cef565,
title = "Insulin and Glucagon: Partners for Life",
abstract = "In August 2016, several leaders in glucagon biology gathered for the European Association for the Study of Diabetes Hagedorn Workshop in Oxford, England. A key point of discussion focused on the need for basal insulin to allow for the therapeutic benefit of glucagon blockade in the treatment of diabetes. Among the most enlightening experimental results presented were findings from studies in which glucagon receptor-deficient mice were administered streptozotocin to destroy pancreatic β cells or had undergone diphtheria toxin-induced β cell ablation. This article summarizes key features of the discussion as a consensus was reached. Agents that antagonize glucagon may be of great benefit for the treatment of diabetes; however, sufficient levels of basal insulin are required for their therapeutic efficacy.",
keywords = "Animals, Blood Glucose, Diabetes Mellitus, Diabetes Mellitus, Experimental, Glucagon, Humans, Hypoglycemic Agents, Insulin, Journal Article, Review",
author = "Holst, {Jens Juul} and William Holland and Jesper Gromada and Young Lee and Unger, {Roger H} and Hai Yan and Sloop, {Kyle W} and Kieffer, {Timothy J} and Nicolas Damond and Herrera, {Pedro L}",
note = "Copyright {\textcopyright} 2017 Endocrine Society.",
year = "2017",
month = apr,
day = "1",
doi = "10.1210/en.2016-1748",
language = "English",
volume = "158",
pages = "696--701",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0013-7227",
publisher = "Oxford University Press",
number = "4",

}

RIS

TY - JOUR

T1 - Insulin and Glucagon

T2 - Partners for Life

AU - Holst, Jens Juul

AU - Holland, William

AU - Gromada, Jesper

AU - Lee, Young

AU - Unger, Roger H

AU - Yan, Hai

AU - Sloop, Kyle W

AU - Kieffer, Timothy J

AU - Damond, Nicolas

AU - Herrera, Pedro L

N1 - Copyright © 2017 Endocrine Society.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - In August 2016, several leaders in glucagon biology gathered for the European Association for the Study of Diabetes Hagedorn Workshop in Oxford, England. A key point of discussion focused on the need for basal insulin to allow for the therapeutic benefit of glucagon blockade in the treatment of diabetes. Among the most enlightening experimental results presented were findings from studies in which glucagon receptor-deficient mice were administered streptozotocin to destroy pancreatic β cells or had undergone diphtheria toxin-induced β cell ablation. This article summarizes key features of the discussion as a consensus was reached. Agents that antagonize glucagon may be of great benefit for the treatment of diabetes; however, sufficient levels of basal insulin are required for their therapeutic efficacy.

AB - In August 2016, several leaders in glucagon biology gathered for the European Association for the Study of Diabetes Hagedorn Workshop in Oxford, England. A key point of discussion focused on the need for basal insulin to allow for the therapeutic benefit of glucagon blockade in the treatment of diabetes. Among the most enlightening experimental results presented were findings from studies in which glucagon receptor-deficient mice were administered streptozotocin to destroy pancreatic β cells or had undergone diphtheria toxin-induced β cell ablation. This article summarizes key features of the discussion as a consensus was reached. Agents that antagonize glucagon may be of great benefit for the treatment of diabetes; however, sufficient levels of basal insulin are required for their therapeutic efficacy.

KW - Animals

KW - Blood Glucose

KW - Diabetes Mellitus

KW - Diabetes Mellitus, Experimental

KW - Glucagon

KW - Humans

KW - Hypoglycemic Agents

KW - Insulin

KW - Journal Article

KW - Review

U2 - 10.1210/en.2016-1748

DO - 10.1210/en.2016-1748

M3 - Review

C2 - 28323959

VL - 158

SP - 696

EP - 701

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0013-7227

IS - 4

ER -

ID: 183007798